Head to Head Contrast: Mateon Therapeutics (OTCMKTS:MATN) vs. Spruce Biosciences (NASDAQ:SPRB)

Mateon Therapeutics (OTCMKTS:MATN) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, risk, profitability, analyst recommendations and dividends.

Analyst Recommendations

This is a summary of recent ratings and price targets for Mateon Therapeutics and Spruce Biosciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mateon Therapeutics	0	0	0	0	0.00
Spruce Biosciences	1	2	5	0	2.50

Spruce Biosciences has a consensus price target of $186.60, indicating a potential upside of 276.82%. Given Spruce Biosciences’ stronger consensus rating and higher possible upside, analysts plainly believe Spruce Biosciences is more favorable than Mateon Therapeutics.

Profitability

This table compares Mateon Therapeutics and Spruce Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mateon Therapeutics	N/A	-64.66%	-42.92%
Spruce Biosciences	N/A	-155.40%	-101.67%

Valuation & Earnings

This table compares Mateon Therapeutics and Spruce Biosciences”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mateon Therapeutics	N/A	N/A	-$6.64 million	($0.02)	-3.00
Spruce Biosciences	$4.91 million	27.74	-$38.97 million	($36.60)	-1.35

Mateon Therapeutics has higher earnings, but lower revenue than Spruce Biosciences. Mateon Therapeutics is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Mateon Therapeutics has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500. Comparatively, Spruce Biosciences has a beta of 3.26, indicating that its share price is 226% more volatile than the S&P 500.

Institutional and Insider Ownership

0.1% of Mateon Therapeutics shares are held by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are held by institutional investors. 39.2% of Mateon Therapeutics shares are held by insiders. Comparatively, 4.3% of Spruce Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Spruce Biosciences beats Mateon Therapeutics on 7 of the 12 factors compared between the two stocks.

About Mateon Therapeutics

Mateon Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.

About Spruce Biosciences

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.